TWD
INDV icon

True Wealth Design’s Indivior Pharmaceuticals INDV Stock Holding History

True Wealth Design’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-59
Closed -$2.12K – 2772
2025
Q4 		$2.12K Buy
+59
New +$1.8K ﹤0.01% 1430

Other funds holding INDV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
OCM
Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

True Wealth Design's INDV Position: Q1 2026 in Review

True Wealth Design sold out of Indivior Pharmaceuticals (INDV) in Q1 2026, closing a stake of 59 shares — an estimated $2.12K sold.

True Wealth Design first reported a position in INDV in Q4 2025 and held it in 1 quarter. The position peaked at $2.12K in Q4 2025. 289 funds tracked by Wall St. Rank hold INDV as of Q1 2026.

  • True Wealth Design reported no remaining Indivior Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • True Wealth Design sold 59 Indivior Pharmaceuticals shares in Q1 2026, an estimated $2.12K.
  • True Wealth Design first reported a position in Indivior Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • True Wealth Design's Indivior Pharmaceuticals position peaked at $2.12K in Q4 2025.
  • 289 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q1 2026.

Based on True Wealth Design's 13F filing for Q1 2026, filed 13 Apr 2026.